ArticleAntimicrobial agents and chemotherapy2006
Time course of microbiologic outcome and gene expression in Candida albicans during and following in vitro and in vivo exposure to fluconazole.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Isolate Specific Transcriptome Changes Exerted by Isavuconazole Treatment in Candida auris.Mycopathologia · 2024Article
- Review
- Genome-wide translational response ofMicrobiology spectrum · 2023Article
- Eucalyptal D Enhances the Antifungal Effect of Fluconazole on Fluconazole-ResistantFrontiers in cellular and infection microbiology · 2019Article
- Host-Pathogen Interactions Mediated by MDR Transporters in Fungi: As Pleiotropic as it Gets!Genes · 2018Review
- Article
- Pathogenesis of Candida albicans biofilm.Pathogens and disease · 2016Review
- Article
- Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infection.Antimicrobial agents and chemotherapy · 2015Article
- Biofilms formed by Candida albicans bloodstream isolates display phenotypic and transcriptional heterogeneity that are associated with resistance and pathogenicity.BMC microbiology · 2014Article
- Recent insights into Candida albicans biofilm resistance mechanisms.Current genetics · 2013Review
- A defect in iron uptake enhances the susceptibility of Cryptococcus neoformans to azole antifungal drugs.Fungal genetics and biology : FG & B · 2012Article
- Potent synergistic effect of doxycycline with fluconazole against Candida albicans is mediated by interference with iron homeostasis.Antimicrobial agents and chemotherapy · 2012Article
- Time-course proteome analysis reveals the dynamic response of Cryptococcus gattii cells to fluconazole.PloS one · 2012Article
- Fungal biofilm resistance.International journal of microbiology · 2012Article
- Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity.Antimicrobial agents and chemotherapy · 2011Article
- Fungal Biofilms: Relevance in the Setting of Human Disease.Current fungal infection reports · 2010Article
- Reverse genetics in Candida albicans predicts ARF cycling is essential for drug resistance and virulence.PLoS pathogens · 2010Article
- Evolutionary divergence in the fungal response to fluconazole revealed by soft clustering.Genome biology · 2010Article
- Role of Ndt80p in sterol metabolism regulation and azole resistance in Candida albicans.Eukaryotic cell · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Pharmacodynamics (PD) considers the relationship between drug exposure and effect. The two factors that have been used to distinguish the PD behaviors of antimicrobials are the impact of concentration on the extent of organism killing and the duration of persistent microbiologic suppression (postantibiotic effect). The goals of these studies were (i) to examine the relationship between antimicrobial PD and gene expression and (ii) to gain insight into the mechanism of fluconazole effects persisting following exposure. Microarrays were used to estimate the transcriptional response of Candida albicans to a supra-MIC F exposure over time in vitro. Fluconazole at four times the MIC was added to a log-phase C. albicans culture, and cells were collected to determine viable growth and for microarray analyses. We identified differential expression of 18% of all genes for at least one of the time points. More genes were upregulated (n=1,053 [16%]) than downregulated (174 [3%]). Of genes with known function that were upregulated during exposure, most were related to plasma membrane/cell wall synthesis (18%), stress responses (7%), and metabolism (6%). The categories of downregulated genes during exposure included protein synthesis (15%), DNA synthesis/repair (7%), and transport (7%) genes. The majority of genes identified at the postexposure time points were from the protein (17%) and DNA (7%) synthesis categories. In subsequent studies, three genes (CDR1, CDR2, and ERG11) were examined in greater detail (more concentration and time points) following fluconazole exposure in vitro and in vivo. Expression levels from the in vitro and in vivo studies were congruent. CDR1 and CDR2 transcripts were reduced during in vitro fluconazole exposure and during supra-MIC exposure in vivo. However, in the postexposure period, the mRNA abundance of both pumps increased. ERG11 expression increased during exposure and fell in the postexposure period. The expression of the three genes responded in a dose-dependent manner. In sum, the microarray data obtained during and following fluconazole exposure identified genes both known and unknown to be affected by this drug class. The expanded in vitro and in vivo expression data set underscores the importance of considering the time course of exposure in pharmacogenomic investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.